Lunchtime Activities
12:45 PM-1:45 PM |
#1. New Statin Role
in Atherosclerosis
Coronary Arena, Level 1
Co-sponsored by AstraZeneca Korea |
| Moderator: Ki Bae Seung |
| 12:45 PM |
Welcome Address |
Ki Bae Seung |
| 12:50 PM |
Optimal Lipid Management: Recent Update
from New Trials |
Peter J. Lansberg |
| 1:10 PM |
Q & A |
|
| 1:30 PM |
Adjourn |
|
|
|
|
#2. Clinical Impact
of the Pro-Healing Stent and Beyond
Endovascular Arena, Level 1
Co-sponsored by Orbus Neich Medical
Korea, Ltd |
| Chairperson: Seung-Jung Park |
| 12:45 PM |
Opening Address |
Seung-Jung Park |
| 12:50 PM |
Development of a Novel Sirolimus Eluting
Pro-Healing Stent  |
Juan Granada |
| 1:05 PM |
Genous Stent in Real-World Experience and
TRIAS HR Pilot Study Long Term Follow Up |
Margo Klomp |
| 1:20 PM |
AMI Intervention in DES Era and Beyond |
Harry Suryapranata |
| 1:35 PM |
Q & A followed by Closing Remarks |
Seung-Jung Park |
| 1:45 PM |
Adjourn |
|
|
|
|
#3. The Future of Drug-Eluting
Stent- BioMatrix™: The New Biodegradable Abluminally Coated
Drug-Eluting Stent with Completely Biodegradable Polymer and a Long
Term Safety Profile of a Bare-Metal Stent
Room 1-1(Calla Room), Level 1
Co-Sponsored by Biosensors &
Jung Sung Medical |
| Moderators: Yangsoo Jang,
Junghan Yoon |
| 12:45 PM |
Welcome and Opening Address |
|
| 12:50 PM |
Assessment of LEADERS 12 Months Result |
Patrick W. Serruys |
| 1:05 PM |
LEADERS: Analysis of 9 Months OCT Results |
Patrick W. Serruys |
| 1:15 PM |
Asia Pacific BioMatrix™ Clinical Results |
Teguh Santoso |
| 1:25 PM |
BioMatrix™: The New Biodegradable
Abluminally Coated DES BioMatrixTM Clinical Program |
Teguh Santoso |
| 1:35 PM |
Questions & Answers |
|
| 1:40 PM |
Conclusion & Closing Remarks |
|
| 1:45 PM |
Adjourn |
|
|
|
|
#4. Prasugrel: A Novel
Thienopyridine Antiplatelet Agent
Room 2-1(Presidio 1 & 2), Level 2
Sponsored by Lilly Korea
& Daiichi Sankyo Korea |
| Moderators: Roxana Mehran,
Seong-Wook Park |
| 12:45 PM |
Welcome Address |
Seong-Wook Park |
| 12:50 PM |
New Paradigms in Treatment of ACS/AMI |
Roxana Mehran |
| 1:10 PM |
Potential Ethnic Difference with Prasugrel
Between Caucasian and Asian Populations |
Ronan Kelly |
| 1:30 PM |
Q & A followed by Closing Remarks |
|
| 1:40 PM |
Adjourn |
|
|
|
|
#5. Vulnerable Plaque:
Identification & Therapeutic Intervention
Symposium Arena, Level 3
Co-sponsored by Clinical Research
Center for Ischemic Heart Disease, The Korea Ministry of Health and
Welfare |
| Moderators: Gary S. Mintz,
Cheol Whan Lee |
| 12:45 PM |
Mechanisms of Plaque Destabilization: Pathologic
Observation |
Renu Virmani |
| 1:00 PM |
In Search of Vulnerable Plaque: Summary
of Current Issues |
Gary S. Mintz |
| 1:15 PM |
Regional Therapy: FIH Experience of A Novel
Self Expandable Nitinol Device |
Juan Granada |
| 1:30 PM |
Systemic Therapy for Plaque Stabilization:
New Drugs Targeting LP-PLA2 |
Patrick W. Serruys |
| 1:45 PM |
Discussion |
|
| 1:50 PM |
Adjourn |
|
|
|
|
#6. Now Is the Switching
Point to Move to the Bivalirudin Monotheraphy
Tutorial Arena, Level 4
Sponsored by Asia Pharm.Ind.Co.,Ltd
|
| Moderators: Young-Hak Kim,
Gregg W. Stone |
| 12:45 PM |
Welcome Address |
Young-Hak Kim |
| 12:50 PM |
STEMI and NSTEMI Pharmacology Confusion:
How to Choose and Use Antithrombins (Unfractionated and Low Molecular
Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents
(Aspirin, Clopidogrel, and Prasugrel) |
Gregg W.Stone |
| 1:10 PM |
Does the Efficacy of Bivalirudin During
PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
| 1:30 PM |
Q & A |
|
| 1:40 PM |
Adjourn |
|
|
|
|
Evening Satellite
Symposia
6:30 PM-9:00 PM |
#1. Next Generation
DES: Today and Tomorrow
Coronary Arena, Level 1
Organized by CVRF, Supported by Educational
Grant from Abbott Vascular & Crossroads Institutes |
| Moderators: Seung-Jung Park,
Gregg W. Stone |
| Panelists:
Hyeon-Cheol Gwon, Hweung Kon Hwang, Myung-Ho Jeong, Hyo-Soo Kim, Do
Sun Lim, Ki Bae Seung, Junghan Yoon |
| 6:45 PM |
Reception Dinner & Opening |
Moderator |
| 7:15 PM |
The Latest Updates in DES Clinical Data |
Gregg W. Stone |
| 7:35 PM |
Real World Experiences of 2nd Generation
DES |
Ian T. Meredith |
| 7:55 PM |
Bioabsorbable Stents- "The New Frontier
in Interventional Cardiology" |
Chuck Simonton |
| 8:15 PM |
Q & A |
|
| 8:35 PM |
Adjourn |
|
|
|
|
#2. The Strength of
Evidence
Endovascular Arena, Level 1
Sponsored by Johnson & Johnson
Medical Korea |
| Moderator: Seong-Wook Park |
| Panelists:
Youngkeun Ahn, Myeong-Ki Hong, Yangsoo Jang, Chong-Jin Kim |
| 6:30 PM |
Opening |
Seong-Wook Park |
| 6:35 PM |
Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years |
Martin B. Leon |
| 6:55 PM |
Panel Discussion |
|
| 7:05 PM |
Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation |
Takeshi Kimura |
| 7:25 PM |
Panel Discussion |
|
| 7:35 PM |
The Impact of Diabetes in the DES Long-Term
Outcome |
Seung-Jung Park |
| 8:00 PM |
Panel Discussion |
|
| 8:10 PM |
Cordis Next-Generation DES Technology |
Robert Falotico |
| 8:30 PM |
Wrap up and Adjourn |
|
| |
|
|
Lunchtime
Activities & Evening Symposia 
